Worth Watching: Zafgen Inc Declines A lot Today, Is Now One of The Worst Performer

Worth Watching: Zafgen Inc Declines A lot Today, Is Now One of The Worst Performer

The stock of Zafgen Inc (NASDAQ:ZFGN) is a huge mover today! About 201,421 shares traded hands. Zafgen Inc (NASDAQ:ZFGN) has declined 42.37% since March 8, 2016 and is downtrending. It has underperformed by 51.69% the S&P500.
The move comes after 9 months negative chart setup for the $103.09M company. It was reported on Oct, 11 by Barchart.com. We have $3.12 PT which if reached, will make NASDAQ:ZFGN worth $11.34M less.

Analysts await Zafgen Inc (NASDAQ:ZFGN) to report earnings on November, 8. They expect $-0.65 earnings per share, up 10.96% or $0.08 from last year’s $-0.73 per share. After $-0.55 actual earnings per share reported by Zafgen Inc for the previous quarter, Wall Street now forecasts 18.18% negative EPS growth.

Zafgen Inc (NASDAQ:ZFGN) Ratings Coverage

Out of 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 1 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 13% are positive. Zafgen Inc has been the topic of 16 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was downgraded by JMP Securities to “Mkt Perform” on Monday, October 19. The firm has “Mkt Perform” rating by Leerink Swann given on Thursday, December 3. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Wednesday, December 2 report. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Outperform” rating given on Thursday, January 21 by RBC Capital Markets. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Buy” rating given on Monday, October 19 by SunTrust. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, October 15. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Outperform” rating given on Thursday, October 15 by FBR Capital. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Mkt Perform” rating given on Wednesday, July 20 by FBR Capital. On Tuesday, August 25 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Neutral” rating given by Suntrust Robinson on Thursday, December 3.

According to Zacks Investment Research, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: Marketwatch.com which released: “Zafgen shares drop more than 40% as drug focus shifted” on July 19, 2016, also Prnewswire.com with their article: “Zafgen, Inc. and Its CEO Sued for Securities Fraud” published on October 21, 2015, Wsj.com published: “Zafgen’s Halted Obesity Treatment Shows Effectiveness” on January 20, 2016. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: Bloomberg.com and their article: “Zafgen Obesity Drug Trial on Hold After Second Patient Death” published on December 02, 2015 as well as Seekingalpha.com‘s news article titled: “Zafgen: Too Cheap To Ignore” with publication date: August 26, 2016.

ZFGN Company Profile

Zafgen, Inc., incorporated on November 22, 2005, is a biopharmaceutical company. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment